Femprox alprostadil: Preliminary Phase II/III data

Preliminary data from a double-blind, placebo-controlled, Chinese Phase II/III trial in 400 patients showed that all 3 doses of Femprox met the endpoint of arousal success rate as determined by FSEP (...